Centogene NV (CNTG) has released an update.
Centogene N.V., a biotech company, has been granted an extension until August 26, 2024, to meet Nasdaq’s minimum Market Value of Publicly Held Shares requirement and avoid delisting. The company is actively working on a strategic review process, which includes a potential sale, to comply with the listing standards. However, the possibility of achieving these milestones and maintaining its Nasdaq listing remains uncertain.
For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
